Takeda‘s Fruzaqla wins UK approval for CRC

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Fruzaqla (fruquintinib) to treat adults with metastatic colorectal cancer (CRC)—to be used when other treatments have not worked. 

This marketing authorization for the oral, chemotherapy-free targeted agent has been granted to Japanese pharma major Takeda (TYO: 4502).

The kinase inhibitor can be used to treat with metastatic CRC who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents, and who have progressed on or are intolerant to treatment with either trifluridine-tipiracil or regorafenib.